Thematic Take is a new product in our portfolio, exploring the impact of a specific technology or macro theme across sectors every month. It is published as a supplement in our digital industry magazines, and as a standalone monthly magazine.

We define a theme as any issue that keeps business leaders awake at night. We help company leaders navigate disruption by tracking these themes across all companies in all sectors.

Position yourself as a leader in the key themes impacting industry by sponsoring our Thematic Take supplements or magazines.

Read our previous supplement: Cybersecurity in the age of AI

Upcoming Thematic Take supplements
December: 2025 Event Guide

For more information about this and other sponsorship opportunities contact Tom McCormick: tom.mccormick@nridigital.com

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: SyngeneGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: PCI Pharma ServicesGo to article: AlfatestLAB - CPHIGo to article: RHEACELL Company InsightGo to article: In DepthGo to article: Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversyGo to article: How the Covid-19 pandemic will help researchers with the mpox emergencyGo to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship effortsGo to article: Clinical research in the UK must build on industry collaboration, says NIHR directorGo to article: Keytruda and Opdivo: a decade reviewGo to article: Alphial - CPHIGo to article: RephineGo to article: Rephine - CPHIGo to article: Thematic Take: AIGo to article: Thematic Take: contentsGo to article: Foreword: Generative AI as a force of creative destructionGo to article: The road to advanced AI capabilitiesGo to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AIGo to article: The impact of AI on the pharma sectorGo to article: Case studies: AI in pharmaGo to article: Latest news: AI in pharmaGo to article: AI boom set to revolutionise healthcare in EuropeGo to article: How NVIDIA grew with the healthcare market instead of pushing into itGo to article: Capturing the genAI boom for drug developmentGo to article: New AI model boosts early osteoporosis diagnosis for ageing populationsGo to article: Impact of AI on metabolic disorder clinical trialsGo to article: Resist temptation to rapidly roll out AI – executives must focus on talent and trainingGo to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021Go to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: Techniconsult Firenze - CPHIGo to article: Science4TechGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue